Sarepta Therapeutics Inc. (SRPT) Rating Increased to Outperform at William Blair
Sarepta Therapeutics Inc. (NASDAQ:SRPT) was upgraded by investment analysts at William Blair from a “market perform” rating to an “outperform” rating in a report issued on Monday. The firm presently has a $88.00 price target on the stock. William Blair’s target price would indicate a potential upside of 57.90% from the company’s current price.
Other analysts have also issued reports about the stock. Vetr raised shares of Sarepta Therapeutics from a “strong sell” rating to a “buy” rating and set a $17.28 price target for the company in a research report on Thursday, June 2nd. WBB Securities reissued a “buy” rating and issued a $40.00 price target on shares of Sarepta Therapeutics in a research report on Wednesday, June 8th. Robert W. Baird reissued a “buy” rating on shares of Sarepta Therapeutics in a research report on Friday, June 10th. Oppenheimer Holdings Inc. reissued a “buy” rating and issued a $60.00 price target on shares of Sarepta Therapeutics in a research report on Sunday, July 17th. Finally, Needham & Company LLC raised their price objective on shares of Sarepta Therapeutics from $20.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, July 22nd. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $51.01.
Sarepta Therapeutics (NASDAQ:SRPT) opened at 55.73 on Monday. The company’s market capitalization is $2.67 billion. Sarepta Therapeutics has a 1-year low of $8.00 and a 1-year high of $56.80. The firm’s 50-day moving average is $28.17 and its 200-day moving average is $21.37.
Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.19) by $0.16. During the same period last year, the firm earned ($0.87) EPS. Equities research analysts predict that Sarepta Therapeutics will post ($4.98) EPS for the current year.
In other news, CEO Edward M. Md Kaye sold 24,557 shares of the firm’s stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of $30.00, for a total value of $736,710.00. Following the sale, the chief executive officer now owns 76,983 shares in the company, valued at $2,309,490. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 10.90% of the stock is currently owned by insiders.
Large investors have recently made changes to their positions in the company. BlackRock Fund Advisors increased its stake in Sarepta Therapeutics by 2.2% in the first quarter. BlackRock Fund Advisors now owns 1,661,818 shares of the company’s stock worth $32,439,000 after buying an additional 36,371 shares in the last quarter. State Street Corp increased its stake in Sarepta Therapeutics by 54.0% in the first quarter. State Street Corp now owns 2,467,376 shares of the company’s stock worth $48,168,000 after buying an additional 865,658 shares in the last quarter. Commonwealth Equity Services Inc acquired a new stake in Sarepta Therapeutics during the second quarter worth $302,000. National Planning Corp increased its stake in Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock worth $242,000 after buying an additional 275 shares in the last quarter. Finally, TIAA CREF Investment Management LLC increased its stake in Sarepta Therapeutics by 5.5% in the first quarter. TIAA CREF Investment Management LLC now owns 216,707 shares of the company’s stock worth $4,230,000 after buying an additional 11,334 shares in the last quarter. Institutional investors and hedge funds own 72.09% of the company’s stock.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.